RxDoctor Payments Data

David Litt, MD

Internal Medicine · Meadowbrook, PANPI 1265403240

Payments from drug & device makers

$4,554in general payments, 2019–2025

Across 304 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novo Nordisk$653
  • AbbVie$563
  • Astellas Pharma US Inc$377
  • GSK$230
  • Axsome Therapeutics, Inc.$181
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,554 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$157,890
Medicare patients
470
Services billed
1,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$170,310
JardianceEmpagliflozin101$92,613
OzempicSemaglutide71$78,595
RybelsusSemaglutide39$63,110
AbrysvoRsv Vacc, Pref A And Pref B/Pf137$43,557
FarxigaDapagliflozin Propanediol29$34,205
JanuviaSitagliptin Phosphate26$23,295
TrulicityDulaglutide15$19,099
XareltoRivaroxaban12$17,863
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,221
SymbicortBudesonide/Formoterol Fumarate29$10,222
Atorvastatin Calcium678$9,740
XanaxAlprazolam16$9,015
ShingrixVaricella-Zoster Ge/As01b/Pf34$7,579
Spiriva RespimatTiotropium Bromide12$6,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$1,411$213,867290 claims
Novo NordiskOzempic, Rybelsus$653$141,705110 claims
Boehringer IngelheimJardiance, Spiriva Respimat$114$98,695113 claims
MerckJanuvia$63$23,29526 claims
GSKTrelegy Ellipta, Shingrix$230$22,80049 claims
Lilly USA, LLCTrulicity$159$19,09915 claims
Johnson & JohnsonXarelto$58$17,86312 claims
AbbVieSynthroid$563$4,75663 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Meadowbrook

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →